A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 BMS-734016 in Patients with Unresectable Stage III or IV Malignant Melanoma - ND
- Conditions
- Malignant unresectable melanoma, stage III or IV.MedDRA version: 6.1Level: HLTClassification code 10027156
- Registration Number
- EUCTR2005-002126-64-IT
- Lead Sponsor
- BRISTOL-M.SQUIBB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 90
Signed written informed consent Target population a Able to comply with visits/procedures required by the protocol b Life expectancy of at least 4 months. c ECOG performance status score 0-1. See Appendix 4 d Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma excluding ocular melanoma . e A pre- and post-treatment fresh core or excision tumor biopsy must be provided for biomarker and predictive marker analyses. It is preferred that the biopsies are obtained from the same organ. Note Site of tumor biopsy should not be the only site of measurable disease. f Measurable disease as defined in Section 3.3.2.2 g Required values for initial laboratory tests WBC 8805; 2500 x 103/mL ANC 8805; 1500 x 103/mL Platelets 8805; 100 x 106/mL Hemoglobin 8805; 10 g/dL Hematocrit 8805; 30 AST 8804; 2 x ULN Bilirubin 8804; 2 x ULN, except patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg/mL; Serum creatinine 8804; 2.0 times the institutional ULN. At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy, hormonal therapy, radiotherapy or major surgery and the beginning of protocol therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin. i Toxicity related to prior therapy must either have returned to 8804; grade 1, baseline, or been deemed irreversible. Age and Sex a Men and women, ages 18 and above. Women of childbearing potential WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before dosing, and while women are on study and for up to 12 weeks after last dose of study drug. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization hysterectomy, bilateral tubal ligation or bilateral oophorectomy or is not postmenopausal defined as amenorrhea 8805; 12 consecutive months; or women on hormone replacement therapy HRT with documented serum follicle stimulating hormone FSH level 35mIU/mL . Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods diaphragm, condoms, spermicides to prevent pregnancy or practicing abstinence or where partner is sterile e.g., vasectomy , should be considered to be of child bearing potential. WOCBP must have a negative pregnancy test minimum sensitivity 25 IU/L or equivalent units of HCG within 72 hours prior to the start of study medication. Men must be willing and able to use an acceptable method of birth control, for at least 3 months after completion of the study, if their sexual partners are WOCBP.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Sex and Reproductive Status a WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the study; b WOCBP using a prohibited contraceptive method; c Women who are pregnant or breastfeeding; d Women with a positive pregnancy test on enrollment or prior to study drug administration; e Sexually active fertile men who are unwilling or unable to use an acceptable method of birth control, for the entire study period and for at least 3 months after completion of the study, if their sexual partners are WOCBP. 2 Target Disease Exclusion a Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix; b Ocular melanoma. 3 Medical History and Concurrent Diseases a Active, untreated central nervous system CNS metastasis including metastasis identified during screening MRI or contrast CT ; b Autoimmune disease Patients with a history of Inflammatory Bowel Disease are excluded from this study as are patients with a history of autoimmune disease e.g. Systemic Lupus Erythematosus, vasculitis, infiltrating lung disease whose possible progression during treatment would be considered by the Investigator to be unacceptable. Patients with a history of well-controlled and/or clinically manageable autoimmune disease e.g. vitiligo, well-controlled thyroid disease, mild psoriasis may be considered for inclusion in consultation with the CRO; c Any underlying medical condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea; d Positive screening tests for HIV, HepB, and HepC. If positive results are not indicative of true active or chronic infection, the patient can be admitted after discussion with and agreement by the BMS Medical Monitor; e Uncontrolled or significant cardiovascular disease including 8722; myocardial infarction within 12 months 8722; uncontrolled angina within 6 months 8722; Class III-IV New York Heart Association NYHA congestive heart failure 8722; diagnosed or suspected congenital long QT syndrome Date 09-Dec-2005 59 Approved v4.0 930011706 3.0 Anti-CTLA-4 CA184004 BMS-734016 Clinical Protocol 8722; any history of clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes . Any patient with a history of any arrhythmia should be discussed with the BMS Medical Monitor prior to entry into the study 8722; prolonged QTc interval on pre-entry electrocardiogram 450 msec 8722; any history of second or third degree heart block may be eligible if currently have a pacemaker 4 Prohibited Therapies and/or Medications a Prior exposure to an anti-CTLA4 antibody. b Use of any immunosuppressing treatments including corticosteroids patients on stable doses of hormone replacement therapy are exempt , cyclosporine, mycophenolate mofetil CellCept 63194; , chemotherapy, radiation, etc, within 4 weeks prior to Day 1 of treatment. c Exposure to any investigational drug or placebo within 4 weeks prior to Day 1 of treatment. d Drugs that are generally accepted to have a risk of causing Torsade
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method